Manhattan Scientifics Stock-Based Compensation 2010-2024 | MHTX
Manhattan Scientifics stock-based compensation from 2010 to 2024. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
Manhattan Scientifics Annual Stock-Based Compensation
(Millions of US $) |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$0 |
| 2019 |
$0 |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$0 |
| 2015 |
$1 |
| 2014 |
$1 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$1 |
| 2010 |
$0 |
| 2009 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Nanotechnology Equipment and Services |
$0.000B |
$0.000B |
|
Manhattan Scientifics Inc. is a technology solutions provider that focuses on the nanomedicine space. The Company acts as a technology incubator that acquires, develops and commercializes life-enhancing technologies in various fields, with emphasis in the areas of alternative energy, and consumer and commercial electronics. Manhattan has three wholly owned subsidiaries of which Metallicum is the only operating subsidiary; and Tamarack and Teneo are dormant. Metallicum is a nanotechnology start-up company that focuses on the development and manufacture of nanostructured metals for medical implants and other applications. Metallicum's initial products include nanostructured bulk metals and alloys in the form of rod, bar, wire and foil. Manhattan Scientifics Inc. conducts its operations primarily in the United States and has its offices in New Mexico, New York and Montreal.
|
